Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 157, Issue 5, Pages 564-579
Publisher
Wiley
Online
2012-03-20
DOI
10.1111/j.1365-2141.2012.09103.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correction: Bone metastasis in prostate cancer: emerging therapeutic strategies
- (2011) Justin Sturge et al. Nature Reviews Clinical Oncology
- The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
- (2010) Hichame Id Boufker et al. BMC CANCER
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts
- (2010) Emilie Flaberg et al. INTERNATIONAL JOURNAL OF CANCER
- The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo
- (2010) Kate Vandyke et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
- (2010) Marc H. G. P. Raaijmakers et al. NATURE
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
- (2009) A. K. Azab et al. BLOOD
- Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability
- (2009) Xin Li et al. CANCER LETTERS
- Dasatinib in relapsed or plateau-phase multiple myeloma
- (2009) Tanya M. Wildes et al. LEUKEMIA & LYMPHOMA
- Enhanced Ex Vivo Expansion of Human Adipose Tissue–Derived Mesenchymal Stromal Cells by Fibroblast Growth Factor-2 and Dexamethasone
- (2009) Sun-Young Lee et al. TISSUE ENGINEERING PART A
- Src as a therapeutic target in men with prostate cancer and bone metastases
- (2008) Fred Saad BJU INTERNATIONAL
- Validation of PDGFR and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
- (2008) A. M. L. Coluccia et al. BLOOD
- Cellular changes in the prostatic stroma of glucocorticoid-treated rats
- (2008) D. L. Ribeiro et al. CELL AND TISSUE RESEARCH
- Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
- (2008) P. Moreau et al. HAEMATOLOGICA
- Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
- (2008) K Vandyke et al. LEUKEMIA
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
- (2008) K Hatano et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started